OncoSignature high- throughput screening platform
March 2015
by  |  Email the author

SHARING OPTIONS:

Horizon Discovery
 
Our OncoSignature HT Screening Platform allows you to profile your compounds of interest as mono or combination therapy across a comprehensive panel of 300 cancer cell lines, including isogenic cell lines. Study drug response, compare activity against 200 oncology reference compounds, identify combination interactions and aid in identifying the best patient population for your drug candidate or drug combination.
 
SEE US AT AACR BOOTH 1055
 
Horizon Discovery
Code:

Back
 
CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.